Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $57.50.

COLL has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after purchasing an additional 538,337 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares during the last quarter. Millennium Management LLC boosted its position in Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Collegium Pharmaceutical by 161.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock valued at $23,692,000 after acquiring an additional 316,109 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Collegium Pharmaceutical by 897.2% during the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after acquiring an additional 242,310 shares in the last quarter.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $35.81 on Friday. The firm has a fifty day moving average of $34.66 and a 200-day moving average of $38.84. Collegium Pharmaceutical has a 52-week low of $29.19 and a 52-week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The firm has a market capitalization of $1.16 billion, a P/E ratio of 17.55 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same quarter in the previous year, the business posted $1.49 EPS. The business’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, analysts predict that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.